Background Hepatitis B virus (HBV) is a common cause of viral hepatitis with significant health complications including cirrhosis and hepatocellular carcinoma. Assays for hepatitis B surface ...

Breakthrough therapy designation recognises the potential of brelovitug to transform the lives of people living with CHD. We look forward to initiating a global pivotal trial a ...

All students must have a series of three Hepatitis B vaccinations (0, 1, and 6 months), and a post-vaccine surface antibody titer (to ... must satisfy this requirement, either by a positive Varicella ...

as the likely negative result would have further pointed towards a false-positive conclusion). Falling antibody titres over the following weeks. Increased awareness and active consideration of the ...

Study: AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis ... people who are either positive for the HBV surface antigen (HBsAg) or HBV core antibody (anti-HBc).

The report highlighted that testing was conducted for the presence of Hepatitis B surface antigen (HBsAg) and antibodies to Hepatitis ... of individuals testing positive for Hepatitis B since ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).